Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

MLA

Scalzulli, Emilia, et al. “Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndrome Patients Treated in the Clinical Practice.” Annals of Hematology, vol. 98, no. 8, Aug. 2019, pp. 1919–25. EBSCOhost, https://doi.org/10.1007/s00277-019-03724-9.

APA

Scalzulli, E., Molica, M., Alunni Fegatelli, D., Colafigli, G., Rizzo, L., Mancini, M., Efficace, F., Latagliata, R., Foà, R., & Breccia, M. (2019). Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology, 98(8), 1919–1925. https://doi.org/10.1007/s00277-019-03724-9

Chicago

Scalzulli, Emilia, Matteo Molica, Danilo Alunni Fegatelli, Gioia Colafigli, Lorenzo Rizzo, Marco Mancini, Fabio Efficace, Roberto Latagliata, Robin Foà, and Massimo Breccia. 2019. “Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndrome Patients Treated in the Clinical Practice.” Annals of Hematology 98 (8): 1919–25. doi:10.1007/s00277-019-03724-9.